Abstract 3123
Background
The use of ICTs has become widespread in recent years. There is little information available in Turkey about the level of usage of ICTs for and by cancer patients.
Methods
This descriptive study was conducted to determine the level of ICTs use and patterns of preferences among cancer patients in Ankara, Turkey. The survey was started on March 2019 and the data collection process is continuing. The sample size was determined as 334 and 173 patients were reached. In data collection, a questionnaire including 38 questions about patient demographics, use of cell phones, the interest of patients in using ICTs to receive information about cancer, and the interest of patients in using ICTs to communicate with health care providers about cancer. The study was approved by university research and ethics committees and informed consent were obtained from patients.
Results
The mean age of the participants was 60.19±12.60 (range 27-89 years), 68.2% were female, 45.7% were primary school graduate. Mean duration of diagnosis was 24.12± 28.56 (range 1-120) months, 26% were breast cancer, 21.4 % had metastasis. Of the total, 78.6% of participants reported that they had access to the internet. The ICTs used at least once a week was found to be respectively WhatsApp (63.5%), Facebook (60.7%), instagram (34.1%), youtube (32.3%) and short message service (SMS) text messaging (31.7%). With regard to the preferences on how patients would like to use ICTs to receive information about diseases, Internet (63.0%), SMS (21.3%) and WhatsApp (19.6%) were widely reported as interesting communication channels. Participants 61.8% rely on information obtained through ICTs. Internet (36.4%), SMS (17.3%) followed by WhatsApp (15.0%, 26/173) were reported as the preferred ICTs through which patients would like to ask health providers about diseases. Adjusted regression analysis showed that patients aged between 45-64 years were more likely to be interested in receiving information through SMS than the oldest group.
Conclusions
In this study, we have determined that SMS text messaging presented the highest rate of interest for receiving information and communicating with health providers, followed by WhatsApp.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract